Page last updated: 2024-11-02

pioglitazone and Graves Disease

pioglitazone has been researched along with Graves Disease in 4 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Graves Disease: A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).

Research Excerpts

ExcerptRelevanceReference
"Until now, the following are not known: (1) the mechanisms underlying the induction of chemokine (C-X-C motif) ligand 10 (CXCL10) secretion by cytokines in thyrocytes; (2) if pioglitazone is able, like rosiglitazone, to inhibit the interferon (IFN)-γ-induced chemokine expression in Graves disease (GD) or ophthalmopathy (GO); and (3) the mechanisms underlying the inhibition by thiazolidinediones of the cytokines-induced CXCL10 release in thyrocytes."7.77Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. ( Antonelli, A; Fallahi, P; Ferrannini, E; Ferrari, SM; Franceschini, SS; Paolicchi, A; Piaggi, S; Salvi, M, 2011)
"Until now, the following are not known: (1) the mechanisms underlying the induction of chemokine (C-X-C motif) ligand 10 (CXCL10) secretion by cytokines in thyrocytes; (2) if pioglitazone is able, like rosiglitazone, to inhibit the interferon (IFN)-γ-induced chemokine expression in Graves disease (GD) or ophthalmopathy (GO); and (3) the mechanisms underlying the inhibition by thiazolidinediones of the cytokines-induced CXCL10 release in thyrocytes."3.77Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. ( Antonelli, A; Fallahi, P; Ferrannini, E; Ferrari, SM; Franceschini, SS; Paolicchi, A; Piaggi, S; Salvi, M, 2011)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Antonelli, A3
Ferrari, SM3
Fallahi, P3
Frascerra, S2
Santini, E1
Franceschini, SS2
Ferrannini, E3
Piaggi, S1
Paolicchi, A1
Salvi, M1
Pupilli, C1
Mancusi, C1
Metelli, MR1
Orlando, C1
Starkey, K1
Heufelder, A1
Baker, G1
Joba, W1
Evans, M1
Davies, S1
Ludgate, M1

Other Studies

4 other studies available for pioglitazone and Graves Disease

ArticleYear
Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
    The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:5

    Topics: Adipocytes; Cells, Cultured; Chemokine CXCL11; Chemokine CXCL9; Dose-Response Relationship, Drug; En

2009
Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.
    Metabolism: clinical and experimental, 2011, Volume: 60, Issue:2

    Topics: Adipocytes; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Chemokine CXCL10; Femal

2011
CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes.
    The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:12

    Topics: Adult; Chemokine CXCL11; Chemokine CXCL9; Cytokines; Female; Fenofibrate; Gemfibrozil; Graves Diseas

2010
Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use?
    The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:1

    Topics: Adipocytes; Adipose Tissue; Anilides; Cell Differentiation; Cells, Cultured; Contraindications; Grav

2003